Background: This study aimed to evaluate the biodistribution of 64 Cu-DOTA-rituximab and its diagnostic feasibility for lymphoma using CD20-targeted 64 Cu-DOTA-rituximab PET/computed tomography (PET/CT).
Methods: A prospective study involving six patients diagnosed with lymphoma was conducted between January 2022 and January 2023. These patients underwent 18 F-fluorodeoxyglucose ( 18 F-FDG) and 64 Cu-DOTA-rituximab PET/CT scans. 64 Cu-DOTA-rituximab PET/CT images were acquired at 1, 24, and 48 h after administering 64 Cu-DOTA-rituximab to assess the biodistribution and dosimetry over time. The observed lymph nodes were categorized into specific regions, including cervical and supraclavicular, axillary and infraclavicular, mediastinal, hilar, abdominal paraaortic and retroperitoneal, iliac, mesenteric, and inguinal regions, to compare the diagnostic ability of 18 F-FDG and 64 Cu-DOTA-rituximab PET/CT in detecting lymphoma lesions. Furthermore, the tumor-to-background ratio was calculated and compared with the maximum standardized uptake (SUV max ) of the tumors and the mean standardized uptake (SUV mean ) of normal organs. Internal radiation dosimetry was determined using the OLINDA/EXM software.
Results: 64 Cu-DOTA-rituximab uptake in lymph nodes associated with lymphoma progressively increased from 1 to 48 h after injection. In contrast, 64 Cu-DOTA-rituximab uptake in normal organs, such as blood, lung, kidney, bladder, muscle, bone, and brain, decreased over time, whereas it increased in the liver and spleen. When it comes to the comparison between 64 Cu-DOTA-rituximab and 18 F-FDG, the SUV max of tumors was higher on 64 Cu-DOTA-rituximab PET/CT (18.1 ± 8.3) than on 18 F-FDG PET/CT (5.2 ± 1.5). Additionally, the tumor-to-background ratio, measured using the SUV mean of normal muscles, was higher on 64 Cu-DOTA-rituximab PET/CT (55.7 ± 31.0) than on 18 F-FDG PET/CT (8.6 ± 2.8). No adverse events related to 64 Cu-DOTA-rituximab injection were reported.
Conclusion: The results of this study demonstrate the feasibility of using 64 Cu-DOTA-rituximab PET/CT to evaluate the CD20 expression. The increased 64 Cu-DOTA-rituximab uptake in lymph nodes associated with tumors, higher SUV max , and tumor-to-muscle ratios observed with 64 Cu-DOTA-rituximab PET/CT compared with 18 F-FDG PET/CT, highlight the diagnostic potential of this imaging modality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MNM.0000000000001889 | DOI Listing |
Nucl Med Commun
October 2024
Department of Nuclear Medicine, .
Background: This study aimed to evaluate the biodistribution of 64 Cu-DOTA-rituximab and its diagnostic feasibility for lymphoma using CD20-targeted 64 Cu-DOTA-rituximab PET/computed tomography (PET/CT).
Methods: A prospective study involving six patients diagnosed with lymphoma was conducted between January 2022 and January 2023. These patients underwent 18 F-fluorodeoxyglucose ( 18 F-FDG) and 64 Cu-DOTA-rituximab PET/CT scans.
Clin Nucl Med
February 2023
From the Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences.
64 Cu-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with 18 F-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible 64 Cu-DOTA-rituximab uptake in the tumor other than lymphoma. 64 Cu-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.
View Article and Find Full Text PDFAnn Nucl Med
May 2021
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Objective: The aim of this study was to evaluate the radiation dosimetry of alpha-emitter Ac-DOTA-rituximab using Monte Carlo simulation of Cu-DOTA-rituximab.
Methods: CD20 expression was evaluated in lymphoma cell lines (Jurkat and Raji). DOTA-rituximab was conjugated and then chelated by Cu.
Mol Imaging Biol
October 2012
Molecular Imaging Program at Stanford, Stanford University, Stanford, CA 94305, USA.
Purpose: This study aims to evaluate (64)Cu-DOTA-rituximab (PETRIT) in a preclinical transgenic mouse model expressing human CD20 for potential clinical translation.
Procedures: (64)Cu was chelated to DOTA-rituximab. Multiple radiolabeling, quality assurance, and imaging experiments were performed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!